he Johnson & Johnson Office of the Chief Medical Officer (OCMO) is a global, functionally independent group responsible for leading safety and championing bioethical principles across Johnson & Johnson’s Pharmaceutical, Medical Device and Consumer Health sectors. Johnson & Johnson’s OCMO is constantly reviewing, monitoring and making decisions regarding the safety of our products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard, to which all our products are held.
Within Johnson & Johnson’s Office of the Chief Medical Officer, safety assessment that is objective and science- and evidence-based is at the core of what we do and is built into every stage of our products’ life cycles—from development to post-launch. But just how do we do it?
The Johnson & Johnson Office of the Chief Medical Officer (OCMO) believes in the collective power of real-world observational data to complement clinical trial findings, and in sharing our insights widely to accelerate important research and policy developments and improve health outcomes for people everywhere.
Sharing of clinical trial data is critical to the advancement of the science that is the foundation of medicine and public health. It furthers our understanding of diseases, expands the base of knowledge needed to develop new treatments and generates new insights and more complete evidence to enable better healthcare decisions for patients.
Bioethics is an applied discipline that takes the principles of ethics and applies them to biological research, science and medicine. Adherence to bioethical principles, including transparency, integrity and respect for the rights and welfare of all persons, stems from Our Credo values and the commitment we make to our patients and consumers.
Our commitment to the safety and well-being of children has been a cornerstone of Johnson & Johnson's work for over 130 years, and we are committed to continue improving medical innovation for children.
Featured
Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.
As Johnson & Johnson’s Vice President and Global Head of Epidemiology, Josh Gagne and his team study real-world data to further understand the safety and effectiveness of our products across many different kinds of patients and clinical environments to help inform important decisions that ultimately improve care for patients
Johnson & Johnson and National Medical Fellowships (NMF) celebrate completing the inaugural cohort’s first year of the innovative three-year service-learning program.
For Baby Safety Month, we sat down with the company's Head of Pediatric Drug Development to learn about its industry-leading Child Health Innovation Leadership Department.
The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
Johnson & Johnson is committed to ethical decision-making and transparency to guide every decision we make. Read more for our scientific policies on sensitive topics.
These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.
We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.
Johnson & Johnson's Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That's where he met Tiko Kerr, who became one of the first patients to take the company's HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.
Their innovative ideas hold promise in solving two of healthcare’s most vexing problems: the nursing shortage and wound care. And Johnson & Johnson is helping them make their high-tech dreams a reality.
Generous parental leave? Check. Support for mental well-being? Check. Here are some of the ways the company stands out when it comes to built-in benefits for its 140,000+ employees.
June 11, 2020These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
June 11, 2020Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
June 11, 2020We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.Back to top
June 11, 2020We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.
